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Abstract
Thromboembolism is a major cause of death in cancer patients. The association between paraneoplastic hypercoa-
gulability of oncological patients and long-term central venous catheters (CVC) may result in CVC associated
thrombosis. Patent Foramen Ovale (PFO), especially when associated with atrial septal aneurysm (ASA) is a risk fac-
tor for paradoxical embolism. We report a case of paradoxical embolism with stroke in an oncological patient with
a huge CVC thrombus playing “ping-pong” with an hypermobile ASA with a PFO. We review the management of
hypercoagulability in oncologic patients and discuss the potential role of routine transthoracic echocardiography
before the implantation of long term central venous catheters to identify predisposing conditions to paradoxical
embolism and select patients for anticoagulant therapy.
Introduction
In oncological patients hemostasis abnormalities range
from asymptomatic alterations to massive thromboem-
bolism. Its clinical importance lies on the fact that it
constitutes the second leading cause of death in cancer
patients [1].
This paraneoplastic hypercoagulability syndrome,
although not completely understood, results secondary
from a complex imbalance between coagulation and
fibrinolysis, for which contributes decreased fibrinogen
and platelet catabolism, reduction of antithrombotic fac-
tors such as proteins S, C and antithrombin, enhanced
platelet activation and aggregation [2], increased forma-
tion of thrombin, and thrombocitosis [3] secondary to
overproduction of thrombopoietin and interleukin 6 by
the tumor [4]. Its severity depends on several factors,
including the type and stage of tumor, the effects of
adjuvant chemotherapy, the presence of central venous
catheters (CVC) for its administration, surgical proce-
dures and other adjuvant therapies [5].
Long-term central venous catheters (CVCs) are com-
monly used in patients with cancer. Their presence may
be complicated by the occurrence of CVC-associated
thrombosis, defined as a mural thrombus extending
from the catheter into the lumen of a vessel and leading
to partial or total catheter occlusion. According to
recent reviews, the incidence of symptomatic and
asymptomatic CVC-associated thrombosis in cancer
patients is much higher than in non selected popula-
tions and ranged between 0-28% and between 12-66%,
respectively [6].
Autopsy reports suggest that a patent Foramen Ovale
(PFO) may occur in 11% to 35% of the normal popula-
tion [7], with a 34.3% age-related incidence for ages
from 0 to 29 years, 25.4% for ages from 30 to 79 years,
and 20.2% for ages between 80 and 99 years. Thompson
and Evans consecutively examined 1100 autopsies and
described a “probe-PFO” (measuring 0.2 to 0.5 cm) in
29% and a “pencil-PFO” (measuring 0.6 to 1.0 cm) in
6% of the cases [7].
Paradoxical embolism was first described by Cohn-
heim in 1877 [7] and refers to an embolus passing from
the right to the left heart through a right-to-left shunt,
leading to arterial embolism. A PFO accounts for 70%
of all right-to-left cardiac shunts. Other reported sources
include a ventricular septal defect, Ebstein’sa n o m a l y ,
pulmonary arteriovenous malformations, and a patent
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any medium, provided the original work is properly cited.ductus arteriosus. With the introduction of transesopha-
geal echocardiography (TEE) the ability to recognize
intracardiac shunting has increased, leading to the
description of a new clinical, impending paradoxical
embolus [7].
A large PFO and the presence of an atrial septal
aneurysm (ASA) have been identified, among others, as
morphological features of PFO with high risk for para-
doxical embolism [8].
Case report
Female patient, 57 years, admitted due to an acute epi-
sode of aphasia without apparent motor deficits.
She had been diagnosed for a colon adenocarcinoma
(Kras wild-type) three years before, with liver and
lung metastasis, being now on chemotherapy
(cetuxime and FOLFOX regimen, which includes foli-
nic acid, 5-fluoruracil and oxaliplatin) delivered
through a permanent CVC catheter implanted in the
superior vena cava.
Three months before the patient had been hospitalized
due to a Listeria monocytogenes bacteraemia, treated
with antibiotics (amoxicillin-clavulamic acid + ceftriax-
one). The patient recovered and was discharged without
neurological deficits.
Fifteen days before the present admission the catheter
had to be replaced because of fever of unknown origin.
The physical examination showed a vigil, lucid and
cooperative patient, with transcortical motor aphasia
(word repetition and understanding maintained), with-
out focal motor deficits or other changes in the neuro-
logical exam.
Figure 1 Transesophageal echocardiography. Huge right atrial mass. Note the hypermobile interatrial septum and the tip of the catheter in
its proximity.
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sion study showed lesions in the left frontal area with
restricted diffusion, consistent with acute ischemic cerebral
vascular lesion on the left middle cerebral artery territory.
The electrocardiogram was normal but the transthoracic
echocardiogram suggested an ASA with a possible PFO.
The TEE showed a voluminous round mass inside the
right atria (see additional file 1), coming from the super-
ior vena cava (see additional files 2 and 3). The mass
seemed to be attached to the proximal and medial part of
the catheter, whose distal tip could be seen free of masses
inside the right atrial cavity (Figures 1 and 2). The ASA
was very mobile, hyperdinamic, beating the mass in every
cardiac cycle, like a racket beating a ball in a ping-pong
match (Figure 3) (see additional files 2, 3 and 4). The
injection of bolus of agitated saline in a forearm vein con-
firmed a small PFO, with small amount of bubbles (less
than 5) in the left heart without provocative Valsalva
manoeuvres (figure 4).
According to the clinical data and to the results of ima-
ging procedures described above our diagnosis was of
an ischemic cerebral vascular accident (CVA) in the ter-
ritory of the left middle cerebral artery by paradoxical
embolism with origin in a thrombus adherent to the
central venous permanent catheter through a PFO in an
ASA.
The patient was empirically treated with antibiotics
and anticoagulation with intravenous unfractionated
heparin (target APTT 2.5× control). Full attention was
given to the risk of fragmentation and multiple embo-
lism by catheter removal and it was decided not to
remove it. Since non-reduction of the thrombus with
anticoagulation was seen, surgery was decided to remove
the thrombus and to proceed to the closure of PFO.
(Figure 5).
In the postoperative period the patient showed clinical
deterioration, with diffuse abdominal pain (uncontrolla-
ble with analgesic therapy) and liver failure attributable
to suprahepatic thrombosis suggesting a Budd-Chiari
syndrome (documented by thoraco-abdominal CT scan
that revealed significant changes involving the hepatic
parenchyma, markedly heterogeneous and with bossela-
dura contour, associated with apparent thrombosis of
the hepatic veins). The patient died about a month after
surgery in multiple organ failure, after a period of coma
induced by opiates for pain control.
Discussion
This case describes the serious consequences of hyper-
coagulability in a patient with a solid tumor, in which
the thrombotic symptoms, despite the successful
removal of a giant thrombus in the right atrium, con-
tributed inexorably to the fatal outcome. Thrombus for-
mation is a rare complication of CVC in non-selected
populations, but its incidence increases in cancer
patients, as a consequence of its paraneoplastic hyper-
coagulability [6].
In our opinion this case report adresses several impor-
tant questions:
How to manage hypercoagulability in cancer patients
with chemotherapy implanted catheters?
Is there any place for antiagregation or long term anti-
coagulation in cancer patients with increased
Figure 2 Transesophageal echocardiography. Bicaval modified view. The origin of the mass is in the superior vena cava, where the catheter
may be seen.
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there is currently no formal recommendations? [9-14].
Schulman [11] and Smorenburg [12] suggested that, in
addition to its antithrombotic mechanisms, warfarin also
could have an antitumoral effect by inhibition of tumor
growth and metasthasis.
Five meta-analyses [6] evaluated the efficacy and safety
of Vitamin K antagonists (VKA) in the prevention of
CVC-associated thrombosis, but none showed that VKA
(either at a fixed low dose or with a target INR between
1.5 and 2.0) exerted a beneficial effect on the occurrence
of symptomatic thromboses versus placebo or no treat-
ment. However, in another meta-analysis, fixed low
doses of VKA were more effective than placebo in
preventing both asymptomatic and symptomatic CVC-
associated thrombosis [relative risk = 0.37 (95% confi-
dence interval 0.26-0.52), P < 0.001) [6]. On the other
hand, and according to several randomized trials in
patients with cancer, low molecular weight heparins did
not show any benefit in preventing symptomatic throm-
bosis of the superior cava vein (though they did not
increase the bleeding risk [6]).
Which other factors increase the thromboembolic risk in
oncological patients?
The chemotherapy regimen also has different prothrom-
botic profile. It seems that patients receiving combina-
tions containing anthracycline, cisplatin or 5-Fluoruracil
Figure 3 Transesophageal echocardiography. Playing games with a thrombus: a dangerous match. The hyperdinamic ASA beats the mass in
every cardiac cycle, like a racket beating a ball in a ping-pong match.
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spontaneous shunt. Note the small amount of bubbles (less than 5) in the left atrium.
Figure 5 The superior vena cava thrombus. Note the similar shape between TEE features (top) and macroscopic data (bottom), with a long
and thin border, corresponding to the insertion in the superior vena cava lumen.
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(animal experimentation microscopic studies with
5-Fluoruracil show severe endothelial damage with
thrombotic formation induced by this agent [15]).
Another important issue is that our patient had pre-
vious bacteremia. Bacteremia is much more common in
patients with catheter thrombosis and thrombosis is
itself a risk factor for catheter infection [15].
Was the surgical approach appropriated in this specific
patient?
In the absence of guidelines, all the therapeutic deci-
sions, specially the one of carrying on with cardiac sur-
gery were intensively debated in multidisciplinary
clinical meetings (internists, neurologists, cardiologists
and cardiac surgeons). To avoid overtreatment, we fol-
lowed a rational stepwise approach: our initial option
was for intravenous non fractionated heparin, which was
infused during 5 days without any reduction of throm-
bus size in a control TEE. We decided not to perform
trombolysis because of the risk of thrombus fragmenta-
tion and of consequent multiple pulmonary and para-
doxical systemic embolization. For the same reason we
decided not to simply pull and remove the CVC,
because thrombus diameter was bigger than the lumen
of the superior vena cava. So, surgery was decided as
the last and difficult option, taking into account the
benefits (to avoid pulmonary and systemic massive
embolism from a huge CVC thrombus playing ping-
pong with an hyperdinamic ASA) versus the risks of the
procedure.
ASA, PFO and paradoxical embolism in oncological
patients
Paradoxical embolism is a known cause of ischemic
CVA in patients with PFO, embolus usually coming
from venous disease of the lower limbs. However, in the
reported case the origin of the thrombus was a bulky
intracardiac mass diagnosed by TEE.
The clinical implications of PFO morphology and
associated features are still debated [16,17]. Qualitative
and quantitative and analysis by TEE is helpful in char-
acterizing PFO-related risk of paradoxical embolism. In
patients with cryptogenic CVAs large and tunnelled
PFO, with “spontaneous” and severe shunt, with conco-
mitant ASA and Chiari network increased the embolic
risk [17]. So, these detailed morphological and func-
tional data should be provided in the TEE assessment of
a PFO, and not only its simple presence or absence.
Conclusion
Thromboembolism is the second major cause of death
in cancer patients and central venous catheter throm-
bosis is very frequent in oncological patients.
Routine transthoracic echocardiography may play an
important role in the work-up of oncological patients
with central venous catheters. This technique may iden-
tify predisposing conditions to paradoxical embolism
and select patients for antiagregant or anticoagulant
therapy. Moreover, in the presence of stroke, if an atrial
septum aneurism and a patent Foramen Ovale is
detected, a transesophageal echocardiogram must be
performed for detailed morphological and functional
definition of the PFO related-risk for paradoxical
embolism.
In the presence of a high-risk PFO the clinical situa-
tion should be discussed in a multidisciplinary medical
team (cardiologist, oncologist, neurologist) and the deci-
sion to start anticoagulation or not should be taken on
an individual basis, taking into account the benefits and
risks of the procedure.
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Additional file 1: The thrombus. Transesophageal echocardiography.
Huge right atrial mass. The origin of the mass is not seen in this view.
Additional file 2: Localizing the mass. Transesophageal
echocardiography. Bicaval modified view. The origin of the mass is in the
superior vena cava, where the catheter may be seen.
Additional file 3: Playing games with a thrombus: a dangerous
match. Transesophageal echocardiography:The hyperdinamic ASA beats
the mass in every cardiac cycle, like a racket beating a ball in a ping-
pong match.
Additional file 4: Playing games with a thrombus: a dangerous
match. Transesophageal echocardiography:The hyperdinamic ASA beats
the mass in every cardiac cycle, like a racket beating a ball in a ping-
pong match. Note some thrombus fragmentation.
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